Cuatrecasas has completed the complete renovation of its Bilbao office (Alameda Mazarredo, 5) to turn it into a more transparent and luminous work environment, in line with the firm’s new ways of working. ‘The refurbishment
Tags :Cuatrecasas
Kusto Group has welcomed Barpimo Coatings, a distinguished family-owned manufacturer of paints and coatings from the Rioja region in northern Spain, to its growing portfolio. Founded by Juan Ros Montesinos, Barpimo has been managed for
The law firms DWF and Cuatrecasas have advised on a structured joint venture with preferred shares for the development of an exclusive residential complex in Cascais (Portugal), promoted by Prime, a firm with significant activity
Cuatrecasas and DLA Piper have advised on the purchase and sale of 100% of the share capital of the Swiss company Mibelle, which specializes in beauty, personal and home care, nutrition and the development of active
Cuatrecasas has hired Sonia Díaz, former director general of the Valencian Tax Agency, as a new partner. With a long career and proven expertise in tax law and management, she will contribute significant value
Cuatrecasas has advised Banco Santander and CaixaBank in the restructuring operation and subsequent judicial approval of the restructuring plan of Grupo Rator, promoted by both banks and the Griñó Group as investor, advised by Gó
Iberian Lawyer unveils the financial data of the country’s largest law firms by income and profitability, highlighting sustained growth
Cuatrecasas has advised the founders and partners of Validated ID on the sale of 100% of its share capital to Signaturit Group, which will expand its offering with new identity verification, authentication and advanced digital signature
The deal also involved the transfer of the right to operate the Estádio Conde Dias Garcia, as well as the other sports infrastructures
Cuatrecasas has advised Deepull Diagnostics in its Series C investment round for 50 million euros. Deepull, a developer of culture-free medical diagnostic solutions, will use the funds to complete clinical validations and advance the regulatory approval
